Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor

Arthritis Research and Therapy

Volumn 13, Issue 6, 2011, Pages

  Kobie, James J ^a   Zheng, Bo ^a   Bryk, Peter ^a   Barnes, Michael ^a   Ritchlin, Christopher T ^a   Tabechian, Darren A ^a   Anandarajah, Allen P ^a   Looney, R John ^a   Thiele, Ralf G ^a   Anolik, Jennifer H ^a   Coca, Andreea ^a   Wei, Chungwen ^a   Rosenberg, Alexander F ^a   Feng, Changyong ^a   Treanor, John J ^a   Lee, F Eun Hyung ^a   Sanz, Ignacio ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; INFLUENZA VACCINE; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; VIRUS ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CONTROLLED STUDY; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN CELL; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; RHEUMATOID ARTHRITIS; SEASONAL INFLUENZA; AGED; BLOOD; CELL CULTURE; COHORT ANALYSIS; DRUG ANTAGONISM; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MIDDLE AGED; VIROLOGY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, VIRAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTE SUBSETS; B-LYMPHOCYTES; CELLS, CULTURED; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; METHOTREXATE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 83455218225     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3542     Document Type: Article

References (33)

1. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Seminars in arthritis and rheumatism 2010, 39:327-346. 10.1016/j.semarthrit.2008.10.002, 19117595.
2. van Assen S, Elkayam O, Agmon-Levin N, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Ioannidis JP, Jayne DR, Kallenberg CG, Müller-Ladner U, Shoenfeld Y, Stojanovich L, Valesini G, Wulffraat NM, Bijl M. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev 2011, 10:341-352. 10.1016/j.autrev.2010.12.003, 21182987.
3. Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol 2010, 6:165-174. 10.1038/nrrheum.2009.279, 3155180, 20142812.
4. Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, Rimmelzwaan GF, Kroon FP. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008, 67:713-716.
5. Gelinck LB, van den Bemt BJ, Marijt WA, van der Bijl AE, Visser LG, Cats HA, Rimmelzwaan GF, Kroon FP. Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible. Vaccine 2009, 27:2469-2474. 10.1016/j.vaccine.2009.02.053, 19368788.
6. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007, 34:272-279.
7. Chan ES, Cronstein BN. Methotrexate--how does it really work?. Nature reviews Rheumatology 2010, 6:175-178. 10.1038/nrrheum.2010.5, 20197777.
8. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003, 3:745-756. 10.1038/nri1184, 12949498.
9. D'Apuzzo M, Rolink A, Loetscher M, Hoxie JA, Clark-Lewis I, Melchers F, Baggiolini M, Moser B. The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4. Eur J Immunol 1997, 27:1788-1793. 10.1002/eji.1830270729, 9247593.
10. Zhang Q, Guo R, Schwarz EM, Boyce BF, Xing L. TNF inhibits production of stromal cell-derived factor 1 by bone stromal cells and increases osteoclast precursor mobilization from bone marrow to peripheral blood. Arthritis Res Ther 2008, 10:R37. 10.1186/ar2391, 2453755, 18371213.
11. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 1996, 184:1397-1411. 10.1084/jem.184.4.1397, 2192824, 8879212.
12. Matsumoto M, Mariathasan S, Nahm MH, Baranyay F, Peschon JJ, Chaplin DD. Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers. Science 1996, 271:1289-1291. 10.1126/science.271.5253.1289, 8638112.
13. Anolik JH, Ravikumar R, Barnard J, Owen T, Almudevar A, Milner EC, Miller CH, Dutcher PO, Hadley JA, Sanz I. Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol 2008, 180:688-692.
14. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, Zheng NY, Mays I, Garman L, Helms C, James J, Air GM, Capra JD, Ahmed R, Wilson PC. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008, 453:667-671. 10.1038/nature06890, 2515609, 18449194.
15. Qian Y, Wei C, Eun-Hyung Lee F, Campbell J, Halliley J, Lee JA, Cai J, Kong YM, Sadat E, Thomson E, Dunn P, Seegmiller AC, Karandikar NJ, Tipton CM, Mosmann T, Sanz I, Scheuermann RH. Elucidation of seventeen human peripheral blood B-cell subsets and quantification of the tetanus response using a density-based method for the automated identification of cell populations in multidimensional flow cytometry data. Cytometry Part B, Clinical cytometry 2010, 78(Suppl 1):S69-82. 3084630, 20839340.
16. Halliley JL, Kyu S, Kobie JJ, Walsh EE, Falsey AR, Randall TD, Treanor J, Feng C, Sanz I, Lee FE. Peak frequencies of circulating human influenza-specific antibody secreting cells correlate with serum antibody response after immunization. Vaccine 2010, 28:3582-3587. 10.1016/j.vaccine.2010.02.088, 2956140, 20298818.
17. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, Mehta A, Razavi B, Del Rio C, Zheng NY, Lee JH, Huang M, Ali Z, Kaur K, Andrews S, Amara RR, Wang Y, Das SR, O'Donnell CD, Yewdell JW, Subbarao K, Marasco WA, Mulligan MJ, Compans R, Ahmed R, Wilson PC. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011, 208:181-193. 10.1084/jem.20101352, 3023136, 21220454.
18. Oracki SA, Walker JA, Hibbs ML, Corcoran LM, Tarlinton DM. Plasma cell development and survival. Immunological Rev 2010, 237:140-159.
19. Salemi S, Picchianti-Diamanti A, Germano V, Donatelli I, Di Martino A, Facchini M, Nisini R, Biselli R, Ferlito C, Podestà E, Cappella A, Milanetti F, Rossi F, Amodeo R, Tabacco F, Di Rosa R, Laganà B, D Amelio R. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity. Clin Immunol 2010, 134:113-120. 10.1016/j.clim.2009.09.014, 19846344.
20. Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, Levartovsky D, Litinsky I, Kaufman I, Wigler I, Mendelson E, Elkayam O. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006, 65:191-194. 10.1136/ard.2005.036434, 1798034, 16014674.
21. Noble GR, Kaye HS, Yarbrough WB, Fiedler BK, Reed CJ, Felker MB, Kendal AP, Dowdle WR. Measurement of hemagglutination-inhibiting antibody to influenza virus in the 1976 influenza vaccine program: methods and test reproducibility. J Infect Dis 1977, 136(Suppl):S429-434. 10.1093/infdis/136.Supplement_3.S429, 342617.
22. Kyu SY, Kobie J, Yang H, Zand MS, Topham DJ, Quataert SA, Sanz I, Lee FE. Frequencies of human influenza-specific antibody secreting cells or plasmablasts post vaccination from fresh and frozen peripheral blood mononuclear cells. J Immunol Methods 2009, 340:42-47. 10.1016/j.jim.2008.09.025, 18996127.
23. Boussiotis VA, Nadler LM, Strominger JL, Goldfeld AE. Tumor necrosis factor alpha is an autocrine growth factor for normal human B cells. Proc Natl Acad Sci USA 1994, 91:7007-7011. 10.1073/pnas.91.15.7007, 44327, 7518925.
24. Di Girolamo N, Visvanathan K, Lloyd A, Wakefield D. Expression of TNF-alpha by human plasma cells in chronic inflammation. J Leukoc Biol 1997, 61:667-678.
25. Cassese G, Arce S, Hauser AE, Lehnert K, Moewes B, Mostarac M, Muehlinghaus G, Szyska M, Radbruch A, Manz RA. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol 2003, 171:1684-1690.
26. Wojciechowski W, Harris DP, Sprague F, Mousseau B, Makris M, Kusser K, Honjo T, Mohrs K, Mohrs M, Randall T, Lund FE. Cytokine-producing effector B cells regulate type 2 immunity to H. polygyrus. Immunity 2009, 30:421-433. 10.1016/j.immuni.2009.01.006, 2745290, 19249230.
27. Li C, Langhorne J. Tumor necrosis factor alpha p55 receptor is important for development of memory responses to blood-stage malaria infection. Infect Immun 2000, 68:5724-5730. 10.1128/IAI.68.10.5724-5730.2000, 101529, 10992477.
28. Liu Z, Jiu J, Liu S, Fa X, Li F, Du Y. Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion. J Autoimmun 2007, 29:187-194. 10.1016/j.jaut.2007.07.004, 17804196.
29. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 2007, 204:33-39. 10.1084/jem.20061531, 2118431, 17200409.
30. Toubi E, Kessel A, Mahmudov Z, Hallas K, Rozenbaum M, Rosner I. Increased spontaneous apoptosis of CD4+CD25+ T cells in patients with active rheumatoid arthritis is reduced by infliximab. Ann N Y Acad Sci 2005, 1051:506-514. 10.1196/annals.1361.095, 16126991.
31. Roosnek E, Lanzavecchia A. Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J Exp Med 1991, 173:487-489. 10.1084/jem.173.2.487, 2118796, 1703209.
32. van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Ioannidis JP, Jayne DR, Kallenberg CG, Müller-Ladner U, Shoenfeld Y, Stojanovich L, Valesini G, Wulffraat NM, Bijl M. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011, 70:414-422. 10.1136/ard.2010.137216, 21131643.
33. Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, Mendelson E, Wigler I, Caspi D, Paran D. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Sem Arth Rheum 2010, 39:442-447.